Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
PHASE3CompletedINTERVENTIONAL
Enrollment
17
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
September 30, 2009
Study Completion Date
September 30, 2009
Conditions
Hepatitis B, Chronic
Interventions
DRUG
peginterferon alfa-2a [Pegasys]
180 mcg sc weekly
Trial Locations (5)
20122
Milan
25125
Brescia
40138
Bologna
42100
Reggio Emilia
43100
Parma
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01237496 - Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253 | Biotech Hunter | Biotech Hunter